Dermavant Presents Results of Tapinarof in Pivotal P-III PSOARING Program at the 29th EADV Virtual Congress
Shots:
- The pivotal P-III clinical program for tapinarof in adult with PsO consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980) PSOARING 3 (NCT04053387)- an ongoing long-term safety study. Positive results of P-III studies were reported in Aug’2020
- Tapinarof previously met the 1EP in separate P-IIb trials for PsO & AD- both studies were published in JAAD. The company anticipates its NDA filling in 2021
- Tapinarof (qd) is a steroid-free- cosmetically elegant- TAMA topical cream being developed for the treatment of PsO and AD. To date- 2200+ subjects have enrolled in 18 clinical trials of tapinarof
Ref: Businesswire | Image: Dermavant
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com